On January 26, 2024, the official website of the State Food and Drug Administration showed that the Semaglutide tablet developed by Novo Nordisk was approved for the market for the treatment of type 2 diabetes. It is also the first oral GLP-1 receptor agonist approved for market in China. Previously, the injectable version of Semaglutide was approved for sale in China in 2021, also for the treatment of type 2 diabetes. On March 24, 2023, Novo Nordisk released data from a Phase 3b clinical trial of an oral version of Semaglutide in the treatment of type 2 diabetes

Pre: The US FDA has approved US WorldMeds' Iwilfin (eflornithine) for the treatment of high-risk neuroblastoma in adults and children

Next: The FDA approved the "weight loss drug" Semaglutide for the prevention of heart disease, which can significantly reduce the risk of major cardiovascular adverse events in obese people